DMA Diamedica Therapeutics

DiaMedica Inc. (TSX VENTURE:DMA), announced today that it has filed a
preliminary short form prospectus in connection with the public offering (the
"Offering") of units of DiaMedica (the "Units"). The Offering is being placed on
a commercially reasonable efforts agency basis by Sora Group Wealth Advisors
Inc. 


Each Unit is currently expected to consist of one common share in the capital
stock of DiaMedica and one-half of one common share purchase warrant, with each
whole warrant entitling the holder thereof to purchase one common share within
two years from the initial closing date of the offering, subject to an
acceleration of the expiry date of such warrants in certain circumstances as
more particularly described in the prospectus. 


The Offering size, price of the Units and the exercise price of the warrants
will be determined by DiaMedica and Sora in the context of the market. 


In addition to the foregoing, DiaMedica intends to complete a non-brokered
private placement in the United States of units of securities of DiaMedica (the
"Concurrent Units") to certain US accredited investors at the same price as the
Units (the "Concurrent Private Placement"). The securities issued under the
Concurrent Private Placement will not be qualified by prospectus. Each
Concurrent Unit will have substantially the same attributes and will be issued
on substantially the same terms as the Units offered pursuant to the Offering.  


It is currently expected that the closing of the Concurrent Private Placement
will take place contemporaneously with the closing of the Offering, however,
closings of the Offering and the Concurrent Private Placement are not
conditional on the other. 


DiaMedica intends to use the net proceeds from the offering and Concurrent
Private Placement for research and development, including a Phase I/II clinical
trial, and for working capital and general and administrative purposes as
described in the prospectus.


About DiaMedica 

DiaMedica is a biopharmaceutical company that develops novel therapeutic
products designed to improve the lives of people with Type 1 diabetes, Type 2
diabetes and other large, medically unmet diseases. DiaMedica's lead product
candidate, DM-199, has been shown to protect and proliferate beta cells and
significantly improve glucose metabolism in preclinical models. 


The Company is listed on the TSX Venture Exchange under the trading symbol 'DMA'. 

FORWARD-LOOKING STATEMENTS

The statements made in this press release that are not historical facts contain
forward-looking information that involves risk and uncertainties. All
statements, other than statements of historical facts, which address DiaMedica's
expectations, should be considered forward-looking statements. Such statements
are based on management's exercise of business judgment as well as assumptions
made by and information currently available to management. When used in this
document, the words "may", "will", "anticipate", "believe", "estimate",
"expect", "intend" and words of similar import, are intended to identify any
forward-looking statements. You should not place undue reliance on these
forward-looking statements. These statements reflect a current view of future
events and are subject to certain risks and uncertainties as contained in the
Company's filings with Canadian securities regulatory authorities. Should one or
more of these risks or uncertainties materialize, or should underlying
assumptions prove incorrect, actual results could differ materially from those
anticipated in these forward-looking statements. The Company undertakes no
obligation, and does not intend, to update, revise or otherwise publicly release
any revisions to these forward-looking statements to reflect events or
circumstances after the date hereof, or to reflect the occurrence of any
unanticipated events. Although management believes that expectations are based
on reasonable assumptions, no assurance can be given that these expectations
will materialize. 


FOR FURTHER INFORMATION PLEASE CONTACT: 
DiaMedica Inc.
Rick Pauls
President and CEO
763-710-4455
info@diamedica.com

DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jun 2024 to Jul 2024

DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jul 2023 to Jul 2024